PLINABULIN (NPI-2358), A NOVEL VASCULAR DISRUPTING AGENT (VDA), IN NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Aren, O. [1 ]
Matamala, L. [1 ]
Reyes, M. [1 ]
Santini, A. [1 ]
McArthur, K.
Lloyd, G. K. [2 ]
Spear, M. A.
机构：
[1] Natl Canc Inst, Santiago, Chile
[2] Nereus Pharmacueticals Inc, Res & Dev, San Diego, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S91 / S92
页数：2
相关论文
共 50 条
  • [1] Phase 1/2 study of the vascular disrupting agent (VDA) plinabulin (NPI-2358) combined with docetaxel in patients with non-small cell lung cancer (NSCLC)
    Heist, Rebecca
    Aren, Osvaldo
    Millward, Michael
    Mainwaring, Paul
    Mita, Alain
    Mita, Monica
    Bazhenova, Lyudmila
    Blum, Robert
    Polikoff, Jonathan
    Gadgeel, Shirish
    Deshmukh, Chetan
    Llyod, G. Kenneth
    Reich, Steven
    Spear, Matthew A.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [2] Safety and pharmacokinetics of the vascular disrupting agent (VDA) NPI-2358 combined with docetaxel for the treatment of non-small cell lung cancer (NSCLC)
    Millward, Michael
    Mainwaring, Paul
    Spear, Matthew A.
    Mita, Monica
    Federico, Kristine C.
    Lloyd, G. K.
    Cropp, Gillian
    Mita, Alain
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S414 - S414
  • [3] Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
    Millward, Michael
    Mainwaring, Paul
    Mita, Alain
    Federico, Kristine
    Lloyd, G. K.
    Reddinger, Natasha
    Nawrocki, Steffan
    Mita, Monica
    Spear, Matthew A.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1065 - 1073
  • [4] Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
    Michael Millward
    Paul Mainwaring
    Alain Mita
    Kristine Federico
    G. K. Lloyd
    Natasha Reddinger
    Steffan Nawrocki
    Monica Mita
    Matthew A. Spear
    Investigational New Drugs, 2012, 30 : 1065 - 1073
  • [5] Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC)
    Mita, A. C.
    Heist, R. S.
    Aren, O.
    Mainwaring, P. N.
    Bazhenova, L.
    Gadgeel, S. M.
    Blum, R. H.
    Polikoff, J.
    Biswas, J.
    Spear, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
    Heist, Rebecca Suk
    Aren, Osvaldo Rudy
    Mita, Alain C.
    Polikoff, Jonathan
    Bazhenova, Lyudmila
    Lloyd, G. Kenneth
    Mikrut, William
    Reich, Steven D.
    Spear, Matthew A.
    Huang, Lan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Phase 1 dose escalation trial of the novel vascular disrupting agent NPI-2358
    Mita, Monica
    Spear, Matthew A.
    Yee, Lorrin K.
    Papadopoulos, K. P.
    Heath, Elisabeth
    Romero, Ofelia
    Lloyd, G. Kenneth
    Cropp, Gillian
    Mita, Alain
    LoRusso, Patricia
    CANCER RESEARCH, 2008, 68 (09)
  • [8] Preclinical profile of NPI-2358, a tumor vascular disrupting agent.
    Lloyd, GK
    Wilson, L
    Bishop, J
    Nicholson, B
    Paladino, M
    Borgström, P
    Honess, DJ
    Tozer, GM
    Siemann, DW
    Mangold, G
    Kiso, Y
    Neuteboom, ST
    Hayashi, Y
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9033S - 9033S
  • [9] Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxel
    Millward, M.
    Mita, A.
    Spear, M. A.
    Federico, K. C.
    Lloyd, G. K.
    Cropp, G.
    Mita, M.
    Mainwaring, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] NPI-2358, a novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV522
    Neuteboom, S.
    Medina, E.
    Palladino, M. A.
    Spear, M. A.
    Lloyd, G. K.
    Nawrocki, S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 141 - 141
12345